グラクソ・スミスクライン

 GSKのチャート


 GSKの企業情報

symbol GSK
会社名 GlaxoSmithKline Plc (グラクソ・スミスクライン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 グラクソ・スミスクライン(GlaxoSmithKline plc)は医療グループであり、ワクチン、市販薬(OTC)及び健康製品等の医薬品の作成、発見、開発、製造及び販売に従事する。同社は主に呼吸器、抗ウイルス、中枢神経系、心血管と泌尿生殖器、代謝、抗菌、腫瘍と嘔吐、皮膚、希少疾患、免疫・炎症、ワクチン及びヒト免疫不全ウイルス(HIV)等の治療分野向けに医薬品を提供している。同社は主に医薬品事業、ワクチン事業、およびコンシューマーヘルスケア事業の3事業区分により構成される。平成24年1月31日、同社は米国とカナダにおけるブランドをPrestige Brands Holdingsに売却完了した。同年8月、同社はHuman Genome Sciencesを買収した。平成25年1月30日、GSKは同社における持ち分の29.3%を追加買収した。  グラクソ・スミスクラインはイギリスの製薬メ―カ―。呼吸器、抗ウイルス、中枢神経、心臓血管、泌尿生殖器、がん、ワクチン、HIV分野で医療用医薬品を展開。主要製品は、鼻炎治療薬、肺疾患治療薬、抗血栓症薬、がん治療薬、抗HIV薬、ジフテリア・インフルエンザワクチンなど。オ―ラルケア製品、禁煙補助薬、市販薬、栄養補助製品などヘルスケア製品も提供。  
本社所在地 980 Great West Road Brentford Middlesex TW8 9GS GBR
代表者氏名 Emma Walmsley
代表者役職名 Chief Executive Officer Executive Director
電話番号 +44 20-8047-5000
設立年月日 36495
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 95490人
url www.gsk.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 12929.04000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 103966.30000
売上高 (百万ドル) 40178.07000
企業価値(EV) (百万ドル) 132783.55500
当期純利益 (百万ドル) 4885.87000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 GlaxoSmithKline plc (ADR) revenues increased 2% to £30.82B. Net income before extraordinary items increased 44% to £3.75B. Revenues reflect Vaccines segment increase of 14% to £5.89B US segment increase of 6% to £11.98B. Net income benefited from Consumer Healthcare segment income increase from £1.37B to £5.74B Unallocated segment loss decrease of 23% to £3.72B. Dividend per share remained flat at £0.80.

 GSKのテクニカル分析


 GSKのニュース

   New MRGPRX2 antagonists identified at GlaxoSmithKline  2022/05/04 13:58:12 BioWorld
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
   GSK’s £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks  2022/05/03 17:46:00 Sky News
The £45bn company that will be created from the demerger of GlaxoSmithKline’s (GSK) consumer products arm is in talks to hire a roster of investment bankers in one of the year’s most prestigious City pitches.
   Swiss scientist convicted of scheme to steal GSK trade secrets  2022/05/02 17:24:40 Reuters
A Swiss scientist has been convicted on charges that he conspired with his sister to steal trade secrets from the drugmaker GlaxoSmithKline to benefit biopharmaceutical companies they established, including one the Chinese government financed.
   GSK, SK bioscience seek approval of COVID vaccine SKYCovione in South Korea, after beating AstraZeneca''s Vaxzevria in trial  2022/04/29 09:50:28 Seeking Alpha
GlaxoSmithKline (GSK) and SK bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety ((KMFDS)) seeking approval of SKYCovione, following…
   GSK and SK bioscience’s COVID vaccine submitted for S.Korea approval  2022/04/29 07:55:50 Financial Post
GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday. GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory […]
   Glaxosmithkline plc - ADR Shares Climb 0.7% Past Previous 52-Week High - Market Mover  2021/12/30 00:54:54 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $110B. The stock is currently up 26.8% year-to-date, up 28.6% over the past 12 months, and up 50.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 42.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -36.1% The company's stock price performance over the past 12 months lags the peer average by -26.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Glaxosmithkline plc - ADR Shares Approach 52-Week High - Market Mover  2021/12/27 09:32:55 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 21.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Glaxosmithkline plc - ADR Shares Close in on 52-Week High - Market Mover  2021/12/26 09:42:21 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Glaxosmithkline plc - ADR Shares Approach 52-Week High - Market Mover  2021/12/24 23:01:37 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 27.8% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -16.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research  2021/12/24 14:35:24 Ken Research
Buy Now According to the report analysis, Global Autoimmune Disorder Drug Delivery Device Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Merck KGaA, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Biogen Inc., GlaxoSmithKline Plc, Johnson Read More » The post Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research appeared first on Ken Research .
   Transdermal Scopolamine Market May Set Huge Growth by 2027 | Baxter International, GlaxoSmithKline, Novartis AG  2021/11/05 10:30:25 OpenPR
The global Transdermal Scopolamine market size is projected to a CAGR of 4.8% during 2021-2027. Motion sickness is becoming more common, and people are becoming more conscious of it, which is fueling the market growth. One of the most important
   Drugmakers, banks lift FTSE 100; IAG down on weak forecast | Business  2021/11/05 09:57:21 Devdiscourse
The blue-chip FTSE 100 gained 0.4% in morning trade, with drugmakers Astrazeneca and GlaxoSmithKline among the top performers. The banking sector rose 0.9% despite UK''s 10-year government bond yields at a one-month low after a surprise decision by the Bank of England on Thursday to hold off on raising interest rates.
   GlaxoSmithKline (NYSE:GSK) Given Equal Weight Rating at Morgan Stanley  2021/11/05 07:06:41 Transcript Daily
GlaxoSmithKline (NYSE:GSK)s stock had its equal weight rating restated by research analysts at Morgan Stanley in a research note issued on Wednesday, The Fly reports. A number of other research firms have also recently commented on GSK. UBS Group reissued a neutral rating on shares of GlaxoSmithKline in a report on Monday, September 20th. JPMorgan []
   Ameritas Investment Company LLC Has $304,000 Stake in GlaxoSmithKline plc (NYSE:GSK)  2021/11/04 13:46:41 Dakota Financial News
Ameritas Investment Company LLC grew its position in GlaxoSmithKline plc (NYSE:GSK) by 64.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 6,497 shares of the pharmaceutical companys stock after buying an additional 2,550 shares during the period. Ameritas Investment Company LLCs holdings in GlaxoSmithKline were worth $304,000 []
   SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights  2021/11/04 10:30:00 Intrado Digital Media
Announced Advancement into Randomized Phase 2 Expansion and Addition of New Sub-studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

 関連キーワード  (医薬品 米国株 グラクソ・スミスクライン GSK )

 twitter  (公式ツイッターやCEOツイッターなど)

GSK動画